A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- Is what I’m feeling a symptom of MS, or is it something else?
- AI analyzes entire gut microbiome to detect MS with high accuracy
- EU regulators approve tolebrutinib, now Cenrifki, for nonrelapsing SPMS
- Late-onset MS linked to relapse-free disability progression: Study
- Real-world study finds fewer MS relapses with Vumerity vs. Tecfidera